Drug Approval | March 27, 2024
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
It is the first autotaxin inhibitor to be investigated in cancer patients
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Ami Organics recently announced contract with global MNC for manufacturing of electrolyte for battery cells
Subscribe To Our Newsletter & Stay Updated
